Showing 1711-1720 of 2657 results for "".
- Texas Tech Medical School to End Use of Race in Admissionshttps://modernod.com/news/texas-tech-medical-school-to-end-use-of-race-in-admissions/2476462/Texas Tech University’s medical school has agreed to end its consideration of race in selecting candidates for admission, an outcome actively sought by the Trump administration. The Texas Tech University Health Sciences Center submitted to pressure from the Education Department’s Offi
- Alcon Acquires Fluid-Based IOL Maker PowerVisionhttps://modernod.com/news/alcon-announces-acquisition-of-powervision/2476387/Alcon announced that it has acquired PowerVision for $285 million plus regulatory and milestone payments starting in 2023. PowerVision’s lens design utilizes the eye’s natural accommodating response to transport fluid in the IOL. While most presbyopia-correcting IOLs use a mult
- RightEye Eye-Tracking System Receives FDA 510(k) Clearancehttps://modernod.com/news/righteye-eye-tracking-system-receives-fda-510k-clearance/2479799/RightEye announced that the company’s vision system has received 510(k) clearance from the FDA. The system records, views, and analyzes eye movements in support of identifying visual tracking impairment in patients. Using advanced eye-tracking technology and analytics, the RightEye s
- Apellis Pharmaceuticals’ APL-2 Receives FDA Fast Track Designation for the Treatment of Patients with GAhttps://modernod.com/news/apellis-pharmaceuticals-apl-2-receives-fast-track-designation-from-fda-for-the-treatment-of-patients-with-geographic-atrophy/2479993/Apellis Pharmaceuticals announced that the FDA has granted fast track designation to the company’s APL-2, a novel inhibitor of complement factor C3 as a next generation monotherapy, for the treatment of patients with geographic atrophy (GA). The FDA’s fast track program faci
- Novartis Exits Antibacterial, Antiviral Researchhttps://modernod.com/news/novartis-exits-antibacterial-antiviral-research/2480028/Novartis will close its antibacterial and antiviral research operations in Emeryville, California as part of CEO Vas Narasimhan’s plans to narrow the drugmaker’s R&D focus. Spokesman Ryan McBride said while “there is a commercial market for these medicines…we do not believe
- Researchers Identify Genetic Variants that May Predict Glaucoma Riskhttps://modernod.com/news/researchers-identify-genetic-variants-that-may-predict-glaucoma-risk/2480146/A study led by scientists from King’s College London, University College London, Massachusetts Eye and Ear, and Harvard Medical School has identified 133 genetic variants that could help predict the risk of developing glaucoma, the world’s leading cause of incurable blindness.
- US Sales of Eylea in First Quarter Best Estimateshttps://modernod.com/news/us-sales-of-eylea-in-first-quarter-best-estimates/2480174/Regeneron Pharmaceuticals reported Thursday that first-quarter sales of Eylea in the US rose 15 percent year-over-year to $984 million, besting analyst estimates of around $922 million. The company’s overall sales increased 15 percent to $1.5 billion, in line with forecasts, as net income s
- Bausch + Lomb Announces the Presentation of New Scientific Data on Products and Pipeline Programs at ASCRShttps://modernod.com/news/bausch-lomb-announces-the-presentation-of-new-scientific-data-on-products-and-pipeline-programs-at-ascrs/2481566/Bausch + Lomb announced the presentation of 21 podium presentations and four poster presentations related to the company’s products and pipeline programs during the A
- Vision Expo West 2022 Opens Hotel Reservationshttps://modernod.com/news/vision-expo-west-2022-opens-hotel-reservations/2480917/The Vision Council and RX, co-organizers of Vision Expo, announced that reservations are now being accepted at Vision Expo West’s partner hotels for
- TearLab Announces Adam Szaronos as President and CEO, and Jim Mazzo as Executive Chairman of the Boardhttps://modernod.com/news/tearlab-announces-adam-szaronos-as-president-and-ceo-and-jim-mazzo-as-executive-chairman-of-the-board/2480506/TearLab announced that Adam Szaronos has been appointed President and Chief Executive Officer by the company's Board of Dir